AllianceBernstein
FULC icon

AllianceBernstein’s Fulcrum Therapeutics FULC Stock Holding History

AllianceBernstein’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$639K Buy
83,370
+48,800
+141% +$297K ﹤0.01% 2590
2026
Q1 		$391K Buy
34,570
+19,300
+126% +$179K ﹤0.01% 2760
2025
Q4 		$173K Sell
15,270
-59,320
-80% -$604K ﹤0.01% 3092
2025
Q3 		$686K Hold
74,590
– – ﹤0.01% 2522
2025
Q2 		$513K Buy
74,590
+9,000
+14% +$48.1K ﹤0.01% 2629
2025
Q1 		$189K Hold
65,590
– – ﹤0.01% 2932
2024
Q4 		$308K Hold
65,590
– – ﹤0.01% 2859
2024
Q3 		$234K Sell
65,590
-157,392
-71% -$1.17M ﹤0.01% 2991
2024
Q2 		$1.38M Buy
222,982
+36,017
+19% +$273K ﹤0.01% 2142
2024
Q1 		$1.76M Sell
186,965
-52,493
-22% -$469K ﹤0.01% 1989
2023
Q4 		$1.62M Buy
239,458
+5,920
+3% +$26.3K ﹤0.01% 2049
2023
Q3 		$1.04M Buy
+233,538
New +$1.02M ﹤0.01% 2225
2023
Q2 		– Sell
-55,900
Closed -$159K – 3196
2023
Q1 		$159K Buy
55,900
+13,100
+31% +$117K ﹤0.01% 2961
2022
Q4 		$312K Buy
42,800
+5,200
+14% +$33.9K ﹤0.01% 2850
2022
Q3 		$304K Buy
37,600
+4,100
+12% +$29.4K ﹤0.01% 2862
2022
Q2 		$164K Buy
33,500
+11,900
+55% +$116K ﹤0.01% 3063
2022
Q1 		$511K Hold
21,600
– – ﹤0.01% 2674
2021
Q4 		$382K Buy
21,600
+5,000
+30% +$99K ﹤0.01% 2851
2021
Q3 		$468K Hold
16,600
– – ﹤0.01% 2778
2021
Q2 		$174K Buy
16,600
+900
+6% +$9.1K ﹤0.01% 3183
2021
Q1 		$185K Hold
15,700
– – ﹤0.01% 3076
2020
Q4 		$184K Hold
15,700
– – ﹤0.01% 3011
2020
Q3 		$125K Buy
15,700
+700
+5% +$8.43K ﹤0.01% 3041
2020
Q2 		$274K Buy
+15,000
New +$236K ﹤0.01% 2919
2019
Q4 		– Sell
-509,369
Closed -$3.38M – 3126
2019
Q3 		$3.38M Buy
+509,369
New +$5.64M ﹤0.01% 1625

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein's FULC Position: Q2 2026 in Review

AllianceBernstein increased its Fulcrum Therapeutics (FULC) stake by 141% in Q2 2026, buying an estimated $297K and bringing the position to 83,370 shares worth $639K. The position accounts for ﹤0.01% of the portfolio, ranked #2590.

AllianceBernstein first reported a position in FULC in Q3 2019 and has held it in 25 quarters since. The position peaked at $3.38M in Q3 2019. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • AllianceBernstein held 83,370 shares of Fulcrum Therapeutics worth $639K as of Q2 2026.
  • AllianceBernstein bought 48,800 Fulcrum Therapeutics shares in Q2 2026, an estimated $297K.
  • Fulcrum Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2590 holding.
  • AllianceBernstein first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 25 quarters since.
  • AllianceBernstein's Fulcrum Therapeutics position peaked at $3.38M in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.